Mode
Text Size
Log in / Sign up

Systemic glucocorticoid exposure in children linked to reversible myocardial hypertrophy, subclinical cardiac changesReview finds reversible heart changes in children taking certain steroid medications

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider reversible myocardial hypertrophy as the most consistent cardiac finding in glucocorticoid-exposed neonates and infants.

This narrative review examined cardiac effects of systemic glucocorticoid exposure in children and adolescents across pediatric conditions requiring repeated or prolonged use. The review did not report specific sample size, study design details, comparator groups, or follow-up duration.

The most consistent structural finding was a time-locked, reversible myocardial hypertrophy phenotype in neonates and young infants. In older children and adolescents, evidence for persistent overt structural damage was sparse and confounded by underlying disease and treatment context. Conventional systolic indices like ejection fraction were frequently preserved, while more sensitive metrics (tissue Doppler parameters, myocardial performance index, strain) could reveal mild, subclinical systolic-diastolic impairment in selected populations.

Direct longitudinal pediatric-to-adult data on hard outcomes like heart failure, coronary events, and atrial fibrillation remain limited. Pediatric glucocorticoid exposure showed clearer dose-time associations with intermediate cardiometabolic risk factors and thromboembolic events than with definitive cardiomyopathy. Key limitations include sparse evidence confounded by underlying disease and treatment context, and limited direct longitudinal pediatric-to-adult data. Safety and tolerability data were not reported.

Current pediatric evidence more strongly supports transient remodeling and risk-factor clustering than definitive, irreversible cardiomyopathy, supporting a plausible mediated pathway to later cardiovascular disease. The evidence is sparse and confounded, requiring cautious interpretation.

Researchers reviewed existing studies on how steroid medications called glucocorticoids might affect the hearts of children and adolescents. These medications are used for various conditions. The review did not involve a new study with a specific number of patients, but instead gathered and analyzed information from past research.

The main finding was that in very young babies, these steroids can cause a temporary thickening of the heart muscle, which appears to go away. In older children, the evidence for permanent heart damage is sparse and hard to separate from the effects of their underlying illness. More sensitive heart tests can sometimes show very mild changes in function that aren't obvious otherwise.

It's important to know this review found no clear proof that these childhood medications cause serious heart problems like heart failure later in life. The link to later heart disease is still a theory based on indirect risk factors. The results are based on limited and sometimes unclear evidence from past studies. This means doctors and families should be aware of the possibility of heart effects, but not assume serious damage is certain.

What this means for you:
Steroids may cause temporary heart changes in infants; evidence for lasting damage in kids is limited.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMar 2026
View Original Abstract ↓
BackgroundSystemic glucocorticoids (GCs) remain indispensable in pediatric care, yet their potential long-term cardiovascular sequelae—particularly after exposure during developmental windows—are incompletely defined.ObjectiveTo synthesize representative clinical evidence linking childhood/adolescent systemic GC exposure with cardiac structure remodeling, subclinical functional alterations, and longer-term cardiovascular outcomes, and to contextualize plausibly mediating pathophysiologic pathways.Evidence synthesisAcross pediatric conditions with repeated or prolonged systemic GC use, the most consistent structural signal is a time-locked, reversible myocardial hypertrophy phenotype in neonates/young infants—often observed during or shortly after dexamethasone exposure and regressing after dose reduction or discontinuation. In older children and adolescents, evidence for persistent, overt structural damage is sparse and confounded by underlying disease and treatment context. Conventional systolic indices (e.g., EF) are frequently preserved, while more sensitive metrics (tissue Doppler–derived parameters, myocardial performance index, strain) can reveal mild, subclinical systolic–diastolic impairment in selected populations (e.g., congenital adrenal hyperplasia). For “hard” adult outcomes (heart failure, coronary events, atrial fibrillation), direct longitudinal pediatric-to-adult data remain limited; however, pediatric GC exposure shows clearer dose–time associations with intermediate cardiometabolic risk factors and thromboembolic events, supporting a plausible mediated pathway to later cardiovascular disease.ConclusionsCurrent pediatric evidence more strongly supports transient remodeling and risk-factor clustering than definitive, irreversible cardiomyopathy. Future studies need long-horizon, indication-aware cohorts with harmonized imaging and event endpoints to quantify exposure–response relationships and identify actionable mediators.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.